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The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect
to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene
expression of selected genes in tumour samples. The interaction between gemcitabine and pemetrexed was synergistic; indeed,
pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as
by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the
key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Bladder tumour specimens showed an heterogeneous gene
expression pattern and patients with higher levels of dCK and hENT1 had better response. Moreover, human nucleoside
concentrative transporter-1 was detectable only in 3/12 patients, two of whom presented a complete response to gemcitabine.
These data provide evidence that the chemotherapeutic activity of the combination of gemcitabine and pemetrexed is synergistic
against bladder cancer cells in vitro and that the assessment of the expression of genes involved in gemcitabine uptake and activation
might be a possible determinant of bladder cancer response and may represent a new tool for treatment optimization.
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Bladder cancer is the fourth cause of death from cancer in the
Western world and its incidence and mortality rates have risen
steadily over the past decade (Parkin et al, 1999; Jemal et al, 2005).
Transitional cell carcinoma (TCC) comprises more than 90% of
all bladder cancers, and superficial tumours (Ta–T1 stages)
account for 70–80% of newly diagnosed TCC. However, despite
the macroscopically complete eradication of the primary lesion,
approximately two-thirds of patients will recur, with a worsening
of tumour grade and stage (Scher et al, 1997). The most effective
approach against superficial bladder cancer is intravesical
immunotherapy with Calmette-Guerin Bacillus, but it is associated
with serious morbidity and it does not result in a significant
survival improvement (Crawford, 2002). Similarly, systemic
combination chemotherapy, such as the methotrexate, vinblastine,
doxorubicin and cisplatin (MVAC) regimen, has proven activity in
advanced bladder cancer, but it exhibits a significant toxicity
burden, with a treatment-related mortality of about 4% (Chester
et al, 2004). Therefore, a great deal of interest has been focused on
research into new drugs or new drug combinations for intravesical
and systemic chemotherapy. In particular, gemcitabine proved to
be active both by intravescical instillation treatment, with minimal
bladder irritation and systemic administration (Moore et al, 1997;
Laufer et al, 2003). Indeed, the gemcitabine-cisplatin combination
is effective and safe and it is now frequently administered as
first-line therapy against metastatic bladder cancer (von der
Maase et al, 2000), although, a significant proportion of patients
are not eligible to receive cisplatin chemotherapy (Chester et al,
2004; Li et al, 2005).
Gemcitabine, a cytotoxic pyrimidine deoxynucleoside analogue,
is transported into the cell mostly by human equilibrative and
concentrative nucleoside transporters (hENT and hCNT, respec-
tively). Cells deficient in hENT1 are highly resistant to gemcitabine
(Mackey et al, 2003) while hCNT1 transfection increases gemci-
tabine sensitivity in pancreatic cancer cell lines (Garcia-Manteiga
et al, 2003). As a prodrug, gemcitabine must be phosphorylated to
its active diphosphate and triphosphate metabolites, which inhibit
ribonucleotide reductase (RR) and DNA synthesis, respectively.
Deoxycytidine kinase (dCK) is the rate-limiting enzyme in the
biotransformation of nucleoside analogs and the increase in dCK
activity may improve the efficacy of gemcitabine (Blackstock et al,
2001). Moreover, dCK activity was related to dCK mRNA levels in
bladder cancer specimens as well as in tumour xenografts,
and preliminary data in esophageal tumours demonstrated a
significant correlation between dCK expression and response to
gemcitabine-based treatment (Sigmond et al, 2004). Furthermore,
high expression of the catabolic enzymes 5’-nucleotidase (5’-NT)
and cytidine deaminase (CDA) has been found in many cell lines
resistant to gemcitabine (Eda et al, 1998; Lotfi et al, 2001). Finally, Revised 5 June 2006; accepted 6 June 2006; published online 25 July 2006
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snon-small cell lung cancer patients with low expression of the M1
subunit of RR (RRM1) significantly benefited from gemcitabine/
cisplatin neoadjuvant chemotherapy (Rosell et al, 2004), while
resistance to gemcitabine was observed both in RRM1 and RRM2
overexpressing cells (Goan et al, 1999; Davidson et al, 2004).
Modulation of enzymes involved in gemcitabine uptake and
metabolism may influence drug activity against human tumour cell
lines and, among chemotherapeutic drugs, pemetrexed appears to
be a potential candidate because of its ability to deplete cellular
nucleotide pools by inhibiting nucleotide synthesis (Giovannetti
et al, 2005). Indeed, pemetrexed and its polyglutamates are potent,
tight-binding inhibitors of folate-dependent enzymes, including
thymidylate synthase (TS), dihydrofolate reductase (DHFR), and
glycinamide ribonucleotide formyltransferase (GARFT) and show
activity against a wide variety of solid tumours, including bladder
cancer (Calvert, 2004). This new multitargeted antifolate may
enhance the expression of hENT1 and dCK as a compensatory
mechanism, potentially favouring gemcitabine activity against
cancer cells. Thus, the primary objective of this study was the
analysis of cellular and genetic aspects underlying the pharmaco-
logical interaction of gemcitabine and pemetrexed in two human
bladder cancer cells. Moreover, this study was aimed at providing a
preliminary characterisation of the expression pattern of hENT1,
hCNT1, dCK, 5’-NT, CDA, RRM1 and RRM2 in surgical specimens
of bladder cancer, in order to find a possible association between
gene expression and response to gemcitabine treatment.
MATERIALS AND METHODS
In vitro studies
Drugs and chemicals Gemcitabine (difluorodeoxycytidine, dFdC)
and pemetrexed (multitargeted antifolate, MTA) were generous
gifts of Eli Lilly (Indianapolis, IN, USA). Drugs were dissolved
in sterile distilled water and diluted in culture medium immedi-
ately before use. McCoy’s medium, fetal bovine serum (FBS),
L-glutamine, penicillin and streptomycin were from Gibco
(Gaithersburg, MD, USA). All other chemicals were from Sigma
Chemical Co. (St Louis, MO, USA).
Cell lines Human bladder TCC cells T24 and J82 were obtained
from American Type Culture Collection (Manassas, VA, USA).
Cells were maintained as monolayer cultures in McCoy’s (T24)
and MEM Eagle (J82) medium, supplemented with 10% fetal
bovine serum, L-glutamine (2mM), penicillin (50IUml
 1) and
streptomycin (50mgml
 1). Cells were cultivated in 75cm
2 tissue
culture flasks (Costar, Cambridge, MA, USA), at 371Ci n5 %C O 2
and 95% air, and harvested with trypsin-EDTA when they were in
logarithmic growth.
Assay of cytotoxicity
Cytotoxicity was assessed by the CellTiter 96 Non-radioactive
cell proliferation kit (Promega, Madison, MA, USA) based on
the cellular metabolism of the tetrazolium compound MTT.
Cells (5 10
4well
 1) were seeded in 1ml of medium in a 12-well
plate and allowed to attach for 24h. Cells were treated with:
(1) gemcitabine (0.3nM–33.3mM) for 1, 6, 24 and 48h; (2)
pemetrexed (2.1nM–212.1mM) for 1, 6, 24 and 48h; (3) gemcita-
bine for 1h, followed by a 24-h washout in drug-free medium, and
then pemetrexed for 24h; (4) pemetrexed for 24h, followed by a
24-h washout in drug-free medium, and then gemcitabine for 1h.
At the end of drug exposure, sample processing was performed as
indicated by the manufacturer. Cell growth inhibition was
expressed as the percentage of the 570nm absorbance relative to
untreated control cultures, measured with a microplate reader
(Multiskan Spectrum, Vantaa, Finland), and the 50% inhibitory
concentration of cell growth (IC50) was calculated by sigmoid
inhibition model (GraphPad PRISM version 4.0; Intuitive Software
for Science, San Diego, CA, USA).
Drug interaction was assessed at a fixed 1:1 concentration
ratio of gemcitabine-pemetrexed by using the combination index
(CI) of Chou et al (1994), where CIo1, CI¼1 and CI41 indicated
synergistic, additive and antagonistic effects, respectively.
Data analysis was performed by the Calcusyn software (Biosoft,
Oxford, UK).
Cell cycle analysis and apoptosis
Cells (10
6well
 1) were plated in 10ml in 100-mm Petri dishes
(Costar) and allowed to grow for 24h. Cells were treated with
gemcitabine (1h), pemetrexed (24h), and their combinations at
concentrations corresponding to IC50 levels and were harvested
immediately after the end of drug exposure or allowed to grow
for additional 24h in drug-free medium. Then cells were washed
twice with PBS and DNA was stained with a solution containing
propidium iodide (25mgml
 1), RNase (1mgml
 1) and Nonidet-
P40 (0.1%). Samples were kept on ice for 30min and cytofluori-
metry was performed using a FACScan (Becton Dickinson, San
Jose ´, CA, USA). Data analysis were carried out with the CELLQuest
(Becton Dickinson) and Modfit softwares (Verity Software,
Topsham, ME, USA).
Apoptosis was evaluated in cells treated with gemcitabine,
pemetrexed and their combinations at IC50 levels, as described in
‘Assay of Cytotoxicity’. At the end of incubation, cells were
washed twice with PBS and fixed in 4% buffered paraformaldehyde
for 15min. Cells were resuspended and incubated for further
15min in a solution containing 8mgml
 1 bisbenzimide chloride.
Cells were spotted on glass slides and examined by fluorescence
microscopy (Leica, Berlin, Germany). A total of 200 cells from
randomly chosen microscopic fields were counted and the
percentage of cells displaying chromatin condensation and nuclear
fragmentation relative to the total number of counted cells
(apoptotic index) was calculated.
Assay of Akt phosphorylation
Akt protein phosphorylation after gemcitabine or pemetrexed
treatment, described above for cell cycle analysis, was assayed
with a P-Ser473 specific ELISA and normalised to the total Akt
content following the manufacturer’s instructions (BioSource
International, Camarillo, CA, USA). P-Ser473 Akt and Akt total
concentrations were calculated from standard curves and values of
P-Ser473 Akt were normalised for total Akt and protein content,
which was measured with the Lowry reagent (Sigma), as described
previously (Giovannetti et al, 2005).
Quantitative PCR analysis of cell lines
Cells were treated with gemcitabine and pemetrexed at IC50 and
IC10 concentration values. RNA was extracted with the QiaAmp
RNA mini Kit (Qiagen, San Diego, CA, USA) according to the
manufacturer’s protocol, dissolved in 10mM dithiothreitol
and 200Uml
 1 RNase inhibitor in Rnase-free water, and measured
by absorbance reading at 260/280nm, using the Uvikon-940
spectrophotometer (Kontron, Milan, Italy). RNA (1mg) was reverse
transcribed at 371C for 1h in 50-ml reaction volume containing
0.8mM dNTPs, 200U of MMLV-RT, 40U of RNase inhibitor
and 0.05mgml
 1 of random primers. The resulting cDNA was
amplified by quantitative PCR with the Applied Biosystems
7900HT sequence detection system (Applied Biosystems, Foster
City, CA, USA). PCR reactions were performed in triplicate using
5ml of cDNA, 12.5ml of TaqMan Universal PCR Master Mix, 2.5ml
of probe and 2.5ml of forward and reverse primers in a final
volume of 25ml. Samples were amplified using an initial incubation
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sat 501C for 5min, followed by incubation at 951C for 10min, 40
cycles of denaturation at 951C for 15s followed by annealing and
extension at 601 for 1min.
Forward and reverse primers and probes for dCK (NM_000788),
cN-II 50-NT (NM_012229), CDA (NM_001785), TS (NM_0010711),
DHFR (NM_000791) and GARFT (NM_000819) were designed
on the basis of the gene sequence obtained from the Gene-
Bank database with the Primer Express software (Applied
Biosystems, V.2.0), as previously described (Giovannetti et al,
2005); while primers and probes for hENT1 (NM_004955), hCNT1
(NM_004213) and for the regulatory M1 (NM_001033), and
catalytic M2 (NM_001034) subunits of RR were obtained from
Applied Biosystems Assay-on-Demand
s products (Hs00168784,
Hs00188418, Hs0035724 and Hs00191940).
Amplifications were normalised to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and quantitation of gene expression in
treated cells was performed using the DDCT calculation, where CT
is the threshold cycle. The amount of target gene, normalised to
GAPDH and relative to the calibrator (untreated control cells), was
reported as percent variation of 2 DDCT with respect to control.
Modulation of gemcitabine uptake, metabolism and
cytotoxicity
Cells plated and treated with gemcitabine alone or in combination
with pemetrexed (0.3nM–33.3mM) as described in ‘Assay of
Cytotoxicity’, were simultaneously exposed to 20-deoxycytidine
(10mM), to inhibit drug activation by phosphorylation (dCK), to
the specific hENT1 inhibitor nitrobenzylthioinosine (NBMPR,
100nM) or to dipyridamole, a non-specific inhibitor of nucleoside
transporters, used at concentration of 10mM, as previously
described (Giovannetti et al, 2005).
Ex vivo studies on human samples of bladder cancer
Patient characteristics and treatment In all, 12 bladder cancer
patients were evaluated in this study. Median age was 61 years
(range, 32–75); five were males and seven females. Six patients
(50.0%) had stage I, while 16.7% had stage II and 33.3% stage III
disease at the time of diagnosis.
Chemotherapy treatment consisted of intravesical gemcitabine
administered every 771 day for 6 consecutive weeks. Gemcitabine
was reconstituted in 0.9% NaCl solution for injection, to a
concentration of 40mgml
 1 and 2000mg were delivered intra-
vescically, through a urethral catheter, which was then removed.
The patient was asked to avoid urination for 1h after gemcitabine
instillation.
Tissue sampling and RNA extraction The experimental protocol
was approved by the local Ethics Committee and patients were
required to sign a consent form to use pathological specimens for
research purposes, prior to their enrolment.
Tissue sampling was performed immediately after transurethral
resection, 7 days before the first instillation of gemcitabine.
Tumours were fragmented, placed in optimal cutting temperature
(OCT) solution (Sakura Finetek Inc., Torrance, CA, USA), and
stored at  801C until extraction of RNA by the TRI REAGENT LS
(Sigma) from tumour fragments homogenised at 41C. RNA
concentration was determined by absorbance reading at 260nm.
Quantitative PCR analysis in tissue samples RNA extracted from
tissue specimens was reverse transcribed in a 50ml reaction volume
and the resulting cDNA was amplified by quantitative, real-time
PCR, as described above in ‘Quantitative PCR analysis of cell lines’.
Preliminary experiments were carried out with dilutions of cDNA
obtained from Quantitative PCR Human Reference Total RNA
(Stratagene, La Jolla, CA, USA) to determine the primer
concentrations that give the minimum s.d. among CT values and
to demonstrate that the efficiencies of amplification of targets and
reference genes (GAPDH) were similar. All reactions were
performed in triplicate, with appropriate nontemplate controls,
and the coefficient of variation (CV) was o1% for all replicates.
Statistical methods
All experiments were performed in triplicate and data were
expressed as mean values7s.d. and were analysed by Student’s
t-test or ANOVA, followed by the Tukey’s test for multiple
comparisons. Demographic and clinical informations were obtained
from medical records. Patients were endoscopically evaluated for
response within 1–4 weeks after the end of treatment, using a
marker lesion, as previously described (Lamm et al, 1995). Indeed,
trials conducted within the EORTC GU and MRC Group using
marker tumours provided evidence that this approach is safe and
ethically acceptable (Van der Meijden et al, 1996).
The relationship between expression of target genes and
response to treatment was evaluated by stratifying patients by
clinical outcome and gene expression values. Data were analysed
using SPSS/PCþ11.5 statistical software (LEAD Technologies, NC,
USA) and statistical significance was set at Po0.05.
RESULTS
Cytotoxicity and pharmacological interaction
Gemcitabine was cytotoxic against T24 and J82 bladder cancer
cells, with IC50s of 91.775.1 and 4366.77833.3nM, after 1h
treatment, and 6.170.4 and 5.771.0nM after 24h exposure,
respectively (Figure 1 and Table 1). A dose-dependent inhibition
of cell growth was also observed in both cell lines after 24 and
48-h pemetrexed exposures, with a higher sensitivity of T24
than J82 cells.
As the CI method recommends a ratio of IC50s values at which
drugs are equipotent, combination studies were performed at
fixed 1:1 (gemcitabine:pemetrexed) concentration ratios in both
bladder cancer cells. The sequential exposure of cell lines to
pemetrexed followed by gemcitabine reduced the IC50so f
gemcitabine to 10.770.7 and 100.077.3nM, in T24 and J82 cells,
respectively, while the IC50s resulting from the reverse sequence
were 47.373.7 and 83.379.7nM (Figure 1). The analysis of drug
interaction revealed a strong synergistic (CIo0.3) at mid- to high
fractions effects using both schedules in T24 and J82 cells, whereas
CI values at fractional effects of 0.25 were close to 1, indicating
moderate synergism or additivity, and CI values at frational effects
of 0.10 displayed some antagonistic effects. The sequence
pemetrexed-gemcitabine proved to be the most effective at all
drug concentrations in T24 cells, while both sequences were almost
equivalent on J82 cells (Figure 2).
Cell cycle activity
Pemetrexed was able to affect the cell cycle of bladder cancer cells
(Table 2). In particular, the percentage of T24 and J82 cells in the
S-phase increased significantly (Po0.05) after treatment with
pemetrexed for 24h. The same effect on T24 cell cycle was
observed after a 1-h treatment with gemcitabine. In contrast flow
cytometry did not show significant perturbation after gemcitabine
exposure in J82 cells (Table 2). Furthermore, drug combinations
demonstrated that both schedules increased the percentage of cells
in the S-phase, while in the J82 cells there was a similar reduction
in the G1 phase (Table 2).
Induction of apoptosis
Bladder cancer T24 and J82 cells exposed to pemetrexed,
gemcitabine and their combinations presented typical apoptotic
Gemcitabine-pemetrexed in bladder cancer cells
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smorphology with cell shrinkage, nuclear condensation and
fragmentation, and rupture of cells into debris. Furthermore, the
occurence of apoptosis was significantly higher in pemetrexed-
treated cells vs controls, whereas gemcitabine exposure was
associated with a lower percentage of apoptotic cells. In each
case, the drug combinations significantly increased the apoptotic
index of bladder cancer cells with respect to controls (Figure 3).
Finally, both drug combinations significantly increased the
apoptotic index of T24 cells with respect to gemcitabine-treated
cells (Po0.05).
Inhibition of Akt phosphorilation
Pemetrexed and gemcitabine significantly reduced the amount of
phosphorylated Akt in T24 cells. In J82 cells, the amount of the
phosphorylated Akt was decreased up to  73.9% by pemetrexed
(Po0.05), while gemcitabine was unable to modulate the
activation of Akt (Figure 4).
Gene expression and chemosensitivity
The relative expression of dCK and hENT1 was higher in T24 and
J82 cells (dCK, 0.89 vs 0.82 and hENT1, 0.88 vs 0.85). Therefore, the
lower chemosensitivity of J82 cells with respect to T24 cells
appeared likely dependent on lower expression of genes encoding
for hENT1 and dCK, which are involved in drug transport and
activation, respectively. A similar correlation was found between
the IC50 values of pemetrexed and the target enzyme TS, its
relative expression being higher (J82) as compared to T24 cells
(TS, 1.02 vs 0.83).
Modulation of dCK, hENT1, TS and GARFT gene
expression
Pemetrexed significantly increased hENT1 expression in both cell
lines (Po0.05). In particular, a 24-h pemetrexed exposure at its
IC50s levels resulted in a three-fold increase in hENT1 expression
in J82 cells (Figure 3). Similar results were observed for dCK,
which expression was increased by pemetrexed up to 57.7% (T24
cells) and 68.2% (J82 cells), respectively (Figure 3) while at IC10
pemetrexed levels here was only a minimal enhancement of hENT1
expression in J82 cells. Moreover, gemcitabine exposure modu-
lated TS and GARFT expression in both cell lines. In particular, TS
expression was significantly decreased up to  81.7 and  74.0% in
J82 and T24 cells, respectively. Similar results on GARFT were
observed at gemcitabine concentration corresponding to its IC50,
GARFT expression being reduced up to  36.04% in J82 cells, while
no significant changes were observed in T24 cells (Figure 3).
Effect of inhibition of gemcitabine metabolism and
transport on cytotoxicity
A key role for dCK and hENT1 on sensitivity of bladder cell lines to
gemcitabine was demonstrated by the increase in IC50 values
after simultaneous treatment with their inhibitors (Table 3). In
particular, incubation with both dipyridamole and NBMPR
resulted in up to 49-fold increase in IC50s, suggesting a pivotal
role for hENT1 in gemcitabine uptake. In contrast, the use of
sequential administration of gemcitabine and pemetrexed partially
prevented the reduction of cytotoxic activity by simultaneous
administration of deoxycytidine in both cell lines. Similar results
were obtained for both schedules with dipyridamole and NBMPR
in T24 cells. However, the use of the drug combinations, totally
protected J82 cells from the reduction of antiproliferative effect
caused by the inhibition of hENT1 (Table 3).
Clinical outcome and response to chemotherapy
Clinical data are available from 12 patients with bladder TCC,
whose tumour specimens underwent a pathologic examination and
were stored in the tissue bank. Patients’ follow-up ranged from 5 to
16 months (median 10.5 months) after surgery. All patients
received gemcitabine, as described above, and were evaluable for
response; two complete responses (16.7%) and 10 stable diseases
(83.3%) were observed.
Gemcitabine-related gene expression levels in patients
The plot on Figure 5 shows the variability of gene expression
observed in patients. The results of gene expression analysis of
tissue samples showed that dCK, 50-NT, CDA, RRM1, RRM2
and hENT1 mRNAs were detectable in all samples, while
hCNT1 mRNA was detectable in only three patients. The gene
expression profile of patients showed a variable pattern. In
particular, dCK was the gene displaying the most pronounced
variability (from 0.611 to 1.095), while the variability of hENT1
(1.09470.102), 50-NT (1.01070.053), CDA (0.91170.058), RRM1
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Figure 1 Concentration-dependent cytotoxicity of gemcitabine (dFdC),
pemetrexed (MTA), and their combinations in T24 and J82 bladder cancer
cells. Each data point represents the percentage of proliferating cells with
respect to untreated control and is the average of three independent
experiments. Bars, s.d.
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s(0.98870.023), and RRM2 (0.92470.051), was moderate, suggest-
ing a possible stratification of patients on the basis of their
expression profile to create homogeneous groups with different
likelihood to respond to gemcitabine treatment. Finally, no
apparent relationships among the expression of different genes
within individual patients were observed.
Association between clinical outcome and gene expression
levels
A significant relationship was observed between clinical response
and expression levels of selected genes (Table 4). In particular,
mean values of dCK and hENT1 were significantly higher in
patients who had a complete pathological response. Furthermore,
hCNT1 expression was detectable only in three patients of whom
two presented complete response. However, the other patient with
detectable hCNT1 expression presented the lowest level of dCK
expression (0.61170.016).
DISCUSSION
Despite the recent advances in the use of chemotherapy in
both local and metastatic bladder cancer, long-term, disease-free
survival rates remain disappointing. During the past decade,
gemcitabine gained widespread use for the treatment of bladder
cancer (Moore et al, 1997; Fechner et al, 2003; Muramaki et al,
2004). Moreover, gemcitabine has shown single-agent response
rates of 28–36% in previously untreated metastatic bladder
patients, with mild myelosuppression (Chester et al, 2004). The
clinical activity of gemcitabine observed in the present work by
the data on complete response and stable disease rates, which were
16.7 and 83.3%, respectively, is in agreement with published data.
Nevertheless, there is a continuing need to develop more
effective cytotoxic chemotherapy regimens, searching for agents
with activity against bladder cancer and low toxicity, as well
as to identify molecular markers that are predictive of response,
in order to select chemotherapeutic agents best suited for the
individual treatment of patients.
Among new drugs, pemetrexed has demonstrated its activity
against a variety of tumour types, including bladder cancer, and it
is generally well tolerated (Fechner et al, 2003).
In preclinical studies, the combination of pemetrexed and
gemcitabine yielded conflicting results. Studies on colorectal
cancer cell lines HCT-8, LoVo, WiDr, LRWZ and Calu-1 lung
cancer cells showed maximal synergistic cytotoxicity when
gemcitabine was followed by pemetrexed in cells (Tesei et al,
2002; Adjei, 2002; Giovannetti et al, 2005). On the contrary, other
Table 1 Cytotoxic effect and pharmacological interaction of gemcitabine and pemetrexed against bladder cancer cell lines
IC50 values (nM)
a
T24 J82
Times (h) Gemcitabine Pemetrexed Gemcitabine Pemetrexed
1 91.775.1 6392.97958.9 4366.77833.3 38194.077638.8
6 35.272.9 156.6726.6 166.7733.3 25642.275384.8
24 6.170.4 64.975.3 5.771.0 2566.97339.4
48 2.170.4 22.572.8 5.270.8 63.674.2
CI values
b
Fa Gemcitabine-Pemetrexed Pemetrexed-Gemcitabine Gemcitabine-Pemetrexed Pemetrexed-Gemcitabine
0.50 0.80 0.17 0.04 0.05
0.75 0.25 0.09 0.03 0.05
0.90 0.09 0.05 0.05 0.09
aIC50s were calculated as mean values7s.d. of at least three MTT independent experiments after 2, 6, 24 and 48h of continuous exposure.
bCombination Index (CI) values were
calculated as mean values from three separate experiments, at fraction affected (FA) of 0.50, 0.75 and 0.90 in cells exposed to gemcitabine and pemetrexed combinations, as
explained in the Materials and methods section.
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Figure 2 Isobologram analysis of pharmacologic interaction of gemcita-
bine (dFdC) – pemetrexed (MTA) combinations in T24 and J82 cells.
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sstudies demonstrated that the schedule-dependent synergism
was maximal when pemetrexed preceded gemcitabine in HT29
colon cancer cells (Tonkinson et al, 1999), MIA PaCa-2, PANC-1
and Capan-1 pancreatic cancer cells (Giovannetti et al, 2004)
and A549 and Calu-6 lung cancer cells (Giovannetti et al, 2005).
In vitro experimental data obtained in the present study
indicate that in bladder cancer T24 cells the highest chemo-
therapeutic synergism was observed with the sequence peme-
trexed-gemcitabine, while both sequences were almost equivalent
in J82 cells.
Understanding the role of cell cycle, apoptosis or other
mechanisms involved in cell death or proliferation, may be crucial
to improve the therapeutic activity of anticancer drug combina-
tions. The synergistic interaction reported in the present study
may be attributed, at least in part, to cell cycle perturba-
tions, inhibition of Akt phosphorilation and modulation of gene
expression. Indeed, cell cycle evaluation demonstrated a shift
towards the S-phase after pemetrexed exposure, potentially faci-
litating gemcitabine activity, and gemcitabine-pemetrexed combi-
nations enhanced apoptosis. These findings are in agreement with
Table 2 Cell cycle modulation after drug treatments, followed by 24-h culture in drug-free medium. Values (%) are means from three independent
experiments and the differences (D) are calculated with respect to controls
Cell lines Treatment G1 phase (DG1) S-phase D(S) G2/M phase D(G2/M)
Control 70.50 27.16 2.34
Gemcitabine (1h) 49.20  21.30 46.57 +19.41 4.32 +1.98
T24 Pemetrexed (24h) 57.05  13.35 39.28 +12.12 3.67 +1.33
Gemcitabine-pemetrexed 72.95 +2.45 23.76  3.4 3.29 +0.95
Pemetrexed-Gemcitabine 74.49 +3.99 16.80  10.36 8.71 +6.37
Control 44.32 39.46 16.22
Gemcitabine (1h) 57.94 +13.62 33.46  6.00 8.60  7.62
J82 Pemetrexed (24h) 37.95  6.37 51.34 +11.88 10.71  5.51
Gemcitabine-pemetrexed 28.90  15.42 61.20 +21.74 9.90  6.32
Pemetrexed-Gemcitabine 24.49  19.83 61.12 +21.66 14.38  1.84
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Figure 3 Percentage of cells with damaged DNA after drug treatments with gemcitabine (dFdC), pemetrexed (MTA) and their combinations in both cell
lines (A). Upper panels, morphological appearance of control and treated cells. Modulation of hENT1 and dCK expression by pemetrexed and modulation
of TS and GARFT expression by gemcitabine in comparison with control in T24 and J82 cells (B). Right panel, representative plot of dCK and GAPDH
expression in control and treated J82 bladder cancer cells. Columns, mean values obtained from three independent experiments; bars, s.d. *Po0.05 with
respect to control, **Po0.05 with respect to gemcitabine.
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sprevious data obtained in colon and pancreatic cells, which were
synchronised after 24-h pemetrexed exposure, and showed a
significant increase of apoptosis after treatment with gemcitabine-
pemetrexed combinations (Tonkinson et al, 1999; Giovannetti
et al, 2004).
One potential antiapoptotic signal transduction system that has
been linked to chemoresistance of human cancer cells is the PI3K-
Akt pathway. In particular, the reduction of phosphorylated Akt
correlated with the enhancement of gemcitabine-induced apopto-
sis and antitumour activity, suggesting that the PI3K-Akt pathway
plays a significant role in mediating drug resistance in several
pancreatic cancer cells (Bondar et al, 2002). Moreover, an
immunohistochemical analysis in patients who underwent curative
resection revealed that p-Akt expression was a prognostic factor
for overall survival in primary pancreatic adenocarcinoma
(Yamamoto et al, 2004). Therefore, the inhibition of Akt might
be a possible molecular target for novel therapeutic strategies and
the present study demonstrated that pemetrexed significantly
decreased the amount of the activated form of Akt.
The present in vitro experimental findings also suggest that the
enhancement of hENT1 and dCK expression by pemetrexed could
be responsible, at least in part, for the synergistic interaction
obtained particularly at mid- to high frational effects with the
sequential exposure to gemcitabine in both T24 and J82 bladder
cell lines. Indeed, hENT1 and dCK gene expression was not
significantly modulated in bladder cancer cells at low fraction
affected (0.10 effect level), potentially explaining drug antagonism.
However, the modulation of TS and GARFT expression by
gemcitabine, potentially favouring pemetrexed activity, could
explain the synergistic interaction observed with the gemcita-
bine-pemetrexed combination, especially in J82 cells. These
results underline the importance of integrating gene expression
analysis for rational development of cytotoxic drug combinations.
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Figure 4 Reduction of P-Ser473 Akt by gemcitabine (dFdC) and
pemetrexed (MTA) in bladder cancer cell lines T24 and J82. *Po0.05 with
respect to control.
Table 3 Effects of modulation of dCK and hENT on gemcitabine (dFdC, 1h) and gemcitabine-pemetrexed (MTA) combinations IC50s( n M) in T24 and
J82 cells. Values are means7s.d. of at least three separate experiments
Cell lines Treatments IC50 +Deoxycytidine +Dipyridamole +NBMPR
dFdC 91.775.1 157.7723.7 4513.47909.5 7475.371337.3
T24 dFdC-MTA 47.375.0 72.3713.7 78.0787.3 67.779.7
MTA-dFdC 10.372.0 12.678.7 49.176.2 48.776.5
dFdC 4366.77833.3 5863.07234.5 4959.77109.1 4476.57801.3
J82 dFdC-MTA 83.3712.0 108.177.7 86.7711.8 85.774.3
MTA-dFdC 100.079.7 111.1712.3 101.372.7 99.775.2
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Figure 5 Gene expression of gemcitabine-related genes in 12 bladder
cancer patients. Values of gene expression were calculated by the GAPDH/
target gene ratio in triplicate experiments.
Table 4 Correlation between clinical response and gene expression
levels in treated patients
Gene expression (ratio with GAPDH)
Clinical response
Gemcitabine
related genes
Complete
response
Stable
disease P
dCK 0.92570.016 0.89270.037 0.037
50-NT 1.00870.057 1.01270.059 0.984
CDA 0.91470.069 0.90970.050 0.617
RRM1 0.98670.031 0.99070.022 0.674
RRM2 0.93170.045 0.91870.050 0.694
hENT1 1.16670.052 1.02170.062 0.040
Values are means7s.d. of triplicate experiments. The shaded area allows the
identification of significant values.
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(Giovannetti et al, 2005), suggesting that modulation of dCK and
hENT1 gene expression as well as inhibition of Akt phosphory-
lation by pemetrexed may be involved in the improvement of
gemcitabine therapeutic potential against several cell lines.
Moreover, a recent study by Achiwa et al (2004) demonstrated
that increased hENT1 expression was a determinant of gemcita-
bine sensitivity, while the decreased dCK expression was
associated with acquired resistance to gemcitabine in lung cancer
cells (Achiwa et al, 2004).
Finally, although the results should be considered very
preliminary and the possible prognostic value of other determi-
nants, such as other intracellular 50-NT, clearly requires to be
evaluated in detail, the present study provides the first evidence of
a significant correlation between gemcitabine chemotherapy
outcome and hENT1, and dCK expression, in bladder cancer
specimens.
These findings are in agreement with a previous study on tissues
from patients with advanced pancreatic cancer. Patients with
detectable hENT1 expression had significantly longer median
survival from gemcitabine initiation than those lacking hENT1 in a
proportion of adenocarcinoma cells (median survival, 13 vs 4
months, P¼0.01) (Spratlin et al, 2004).
Similar results were obtained in a pharmacogenetic study on 83
pancreatic cancer patients where PCR analysis demonstrated that
overall survival was significantly longer in patients with high
hENT1 expression, with respect to patients with low hENT1 levels
(median, 25.7, 95% CI, 17.6–33.7 vs 8.5, 95% CI, 7.0–9.9 month)
and the multivariate analysis confirmed the prognostic signifi-
cance of hENT1 (Giovannetti et al, 2006).
In addition, several in vitro studies demonstrated that
several cancer cell lines incorporate gemcitabine mostly via the
hENT1 and hCNT1 transporters and that treatment of cells
with nucleoside transport inhibitors NBMPR or dipyrida-
mole markedly reduced the sensitivity to gemcitabine (Mackey
et al, 2003).
The crucial role of hENT1 was confirmed in the present work by
the marked reduction of gemcitabine activity with the nucleoside
transport inhibitors which was partially circumvented after
exposure to drug combinations, confirming the ability of
pemetrexed to increase hENT1 expression. Furthermore, tran-
scription analysis in untreated cells suggested the predictive
value of expression of both hENT1 and dCK, while, as previously
reported in lung and colon cancer cells, a similar correlation
was found between TS and chemoresistance to pemetrexed
(Sigmond et al, 2003; Giovannetti et al, 2005). Indeed, preclinical
studies have also shown that pretreatment dCK expression
level could be used as a predictive parameter of tumour sensitivity
and a clear correlation between dCK activity and gemcitabine
sensitivity was observed in several tumour xenografts (Kroep
et al, 2002). Moreover, dCK mRNA expression in leukaemic
blasts at diagnosis was correlated with clinical outcome in patients
with acute myeloid leukaemia treated with cytarabine (Galmarini
et al, 2003).
In light of these findings, we conclude that (1) gemcitabine and
pemetrexed synergistically interact against bladder cancer cells,
through suppression of Akt phosphorylation and induction of
apoptosis; (2) pemetrexed enhances dCK and hENT1 expression in
both cell lines thus suggesting that the sequence pemetrexed-
gemcitabine is mostly rationally designed; (3) the transcrip-
tion analysis of gemcitabine-related genes in bladder cancer
specimens is feasible and might be useful to help select patients
with the highest likelyhood to enjoy complete response after
gemcitabine therapy.
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